Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How Bad Are Biomedical Innovation Problems? Metrics Needed To Know For Sure

This article was originally published in The Pink Sheet Daily

Executive Summary

Panel at Brookings Institution conference says there is no comprehensive measure and the issue is more complex than just tracking R&D spending and FDA approvals.


Related Content

“Complete Response” Letters Might Include Benefit-Risk Framework Discussion
BIO Looking For Clinical Trial Reform Priorities
Should FDA Be Forced To Consider Development Time And Cost?
Pre-IND, End-Of-Phase II Meetings Can Decrease Development Time, FDA Says
Reimbursement As Important As Regulatory Risks In Investment Decisions – Venture Capitalist
FDA Drug Review Costs Rise, But Personnel Spending Flattens
Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts